Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin

Acta Veterinaria Scandinavica

Takae Shimizu²  Kazuki Harada¹  Yasushi Kataoka² 

[1] Department of Veterinary Internal Medicine, Tottori University, Minami 4-101, Koyama-Cho, Tottori-Shi, Tottori, 680-8553, Japan

[2] Laboratory of Veterinary Microbiology, Nippon Veterinary and Life Science University, 1-7-1, Kyonan-cho, Musashino, Tokyo, 180-8602, Japan

关键词: Canines;    Staphylococcus pseudintermedius;    Pseudomonas aeruginosa;    Escherichia coli;    Fluoroquinolone;    Mutant prevention concentration;   

Others  :  789343
DOI  :  10.1186/1751-0147-55-37

 received in 2012-12-03, accepted in 2013-02-10,  发布年份 2013

【 摘 要 】

Background

The mutant prevention concentration (MPC) is an important parameter to evaluate the likelihood of growth of fluoroquinolone-resistant mutants for antimicrobial-pathogen combinations. The MPCs of fluoroquinolones for different canine pathogens have not been compared. In this study, we compared for the first time orbifloxacin MPCs between susceptible strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.

Methods

More than 10¹⁰ CFU/ml of 10 strains of each bacterial species were inoculated onto Muller-Hinton agar supplemented with different concentrations of orbifloxacin from 1× to 64× minimum inhibitory concentration (MIC) and the MPCs were recorded. MICs of original strains and of mutants arising after exposure to sub-MPC concentrations (one per original strain) were determined in the presence or absence of efflux pump inhibitors (EPIs). The effects of quinolone resistance-determining region (QRDR) mutations were also examined.

Results

MPCs were significantly higher for P. aeruginosa (16–128 μg/ml) than for E. coli (0.5–32 μg/ml). MPCs for S. pseudintermedius varied between the low-susceptible (16–128 μg/ml) and the high-susceptible strains (4–16 μg/ml) and were the most broadly distributed among the three species. Regarding resistance mechanisms, only one QRDR mutation in gyrA was found in all of the 10 mutants of E. coli and in 4 of the 10 mutants of P. aeruginosa, whereas mutations in both grlA and gyrA were found in 3 mutants and one mutation in grlA was found in 2 mutants among the 10 mutants of S. pseudintermedius. In the presence of an EPI, the MICs of P. aeruginosa mutants decreased markedly, those of E. coli mutants decreased moderately, and those of S. pseudintermedius mutants were unaffected.

Conclusions

MPCs of orbifloxacin vary between bacterial species of canine pathogens, possibly due to the diversity of the main fluoroquinolone resistance mechanism among these species. Therefore, the type of bacterial species should be taken into consideration when using fluoroquinolone drugs such as orbifloxacin in canines.

【 授权许可】

   
2013 Shimizu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Harada K, Arima S, Niina A, Kataoka Y, Takahashi T: Characterization of Pseudomonas aeruginosa isolates from dogs and cats in Japan: current status of antimicrobial resistance and prevailing resistance mechanisms. Microbiol Immunol 2012, 56:123-127.
• [2]Harada K, Niina A, Nakai Y, Kataoka Y, Takahashi T: Prevalence of antimicrobial resistance in relation to virulence genes and phylogenetic origins among urogenital Escherichia coli isolates from dogs and cats in Japan. Am J Vet Res 2012, 73:409-417.
• [3]Onuma K, Tanabe T, Sato H: Antimicrobial resistance of Staphylococcus pseudintermedius isolates from healthy dogs and dogs affected with pyoderma in Japan. Vet Dermatol 2012, 23:17-e5.
• [4]Blondeau JM: New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol 2009, 20:383-396.
• [5]Gebru E, Choi MJ, Lee SJ, Damte D, Park SC: Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. J Med Microbiol 2011, 60:1512-1522.
• [6]Gebru E, Damte D, Choi MJ, Lee SJ, Kim YH, Park SC: Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs. Vet Microbiol 2012, 154:384-394.
• [7]Awji EG, Tassew DD, Lee JS, Lee SJ, Choi MJ, Reza MA, Rhee MH, Kim TH, Park SC: Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius. Vet Dermatol 2012, 23:376-380.
• [8]Piddock LJ: Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs 1999, 58(Suppl 2):11-18.
• [9]Laboratory NVA: Ministry of Agriculture, Forestry and Fisheries: Sales Amounts and Sales Volumes (Active Substance) of Antibiotics, Synthetic Antibacterials. Tokyo, Japan: Antihelmintics and Antiprotozoals; 2011.
• [10]Sasaki T, Tsubakishita S, Tanaka Y, Sakusabe A, Ohtsuka M, Hirotaki S, Kawakami T, Fukata T, Hiramatsu K: Multiplex-PCR method for species identification of coagulase-positive staphylococci. J Clin Microbiol 2010, 48:765-769.
• [11]Pasquali F, Manfreda G: Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet Microbiol 2007, 119:304-310.
• [12]Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard - Third Edition. PA: CLSI document M31-A3 Wayne; 2008.
• [13]Akasaka T, Tanaka M, Yamaguchi A, Sato K: Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001, 45:2263-2268.
• [14]Lee YJ, Cho JK, Kim KS, Tak RB, Kim AR, Kim JW, Im SK, Kim BH: Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken. J Microbiol 2005, 43:391-397.
• [15]Intorre L, Vanni M, Di Bello D, Pretti C, Meucci V, Tognetti R, Soldani G, Cardini G, Jousson O: Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi. J Vet Pharmacol Ther 2007, 30:464-469.
• [16]Walker RD: The use of fluoroquinolones for companion animal antimicrobial therapy. Aust Vet J 2000, 78:84-89.
• [17]Yoshida H, Bogaki M, Nakamura M, Nakamura S: Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990, 34:1271-1272.
• [18]Oram M, Fisher LM: 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 1991, 35:387-389.
• [19]Webber M, Piddock LJ: Quinolone resistance in Escherichia coli. Vet Res 2001, 32:275-284.
• [20]Chang TM, Lu PL, Li HH, Chang CY, Chen TC, Chang LL: Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother 2007, 19:488-494.
• [21]Olofsson SK, Marcusson LL: Komp Lindgren P, Hughes D, Cars O: Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model; relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006, 57:1116-1121.
• [22]Matsumoto S, Takahashi M, Yoshida M, Komatsu T, Kitadai Y, Horii Y, Katae H: Absorption, distribution and excretion of orbifloxacin in dogs and cats. J Jap Vet Med Assoc 1997, 50:470-474. in Japanese with English summary
• [23]Kay-Mugford PA, Weingarten AJ, Ngoh M, Zolynas R, White A, Katz T, Simmons R, Varma KJ: Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet Ther 2002, 3:402-408.